

Incidence and timing of taper/posttherapy-Emergent adverse events following discontinuation of desvenlafaxine 50 mg/d in patients with major depressive disorder

Ninan PT, Musgnung J, Messig M, Buckley G, Guico-Pabia CJ, Ramey TS.

Primary care companion to the journal of clinical psychiatry

2015; 17(1)

ARTICLE IDENTIFIERS

DOI: 10.4088/PCC.14m01715

PMID: unavailable

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: sn 99008265

pISSN: 1523-5998

eISSN: 1555-211X

OCLC ID: 40720024

CONS ID: not available

US National Library of Medicine ID: 100887410

This article was identified from a query of the SafetyLit database.